


## V940-009 Study Design

A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants with **Resectable** Stage II-IIIB (N2) NSCLC not Achieving **pCR** after receiving Neoadjuvant Pembrolizumab with Platinum-based Doublet Chemotherapy (INTERpath-009)



## V940-009重點篩選納入條件

1. 病理學證實確診患有NSCLC，期別是**可切除的第II、IIIA或IIIB（N2）期**，且"先前未經治療"（在指定的前導性治療和手術後納入的受試者除外）
5. 確認沒影表皮生長因子受體（EGFR）突變（文件紀錄證實沒有腫瘤活化型EGFR突變[例如：DEL19或L858R]）

重點篩選排除條件 (鱗狀細胞癌患者不需)

1. 診斷為小細胞肺癌（SCLC），或者是混合型腫瘤而存在小細胞成分等
2. 有報告的文件紀錄顯示具有間變性淋巴瘤激（ALK）基因重組
14. 有間質性肺病之病史

手術分期別都要求: **Surgery must be a lobectomy, bilobectomy, pneumonectomy, sleeve lobectomy, sleeve**

**pneumonectomy, or chest wall resection** with any of the previously listed resections.

Please note that wedge resection or **segmentectomy is NOT permitted.**